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Translational Relevance 
 
The majority of patients with epithelial ovarian cancer have advanced stage disease at the time of 
diagnosis.  More than half will relapse and die within five years.  While anti-angiogenic treatment plays a 
crucial role in ovarian cancer, no biomarker has been established to identify patients benefiting most from 
this treatment. In this study, we test for a correlation between molecular subtype and outcome after 
treatment with bevacizumab in a randomized controlled phase III trial of primary ovarian cancer. 
Importantly, rather than create a de novo molecular classification, we utilized molecular subtypes 
previously described by the Australian Ovarian Cancer Study and validated by The Cancer Genome 
Atlas. We demonstrate that molecular subtypes with the poorest survival (proliferative and mesenchymal) 
derive a comparably greater benefit from treatment which includes bevacizumab. Taken together, this 
data indicates that stratifying patients by molecular subtype could be an effective therapeutic strategy for 
ovarian cancer. 
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ABSTRACT 
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Purpose: Recent progress in understanding the molecular biology of epithelial ovarian cancer has 
not yet translated into individualized treatment for these women or improvements in their disease 
outcome. Gene expression has been utilized to identify distinct molecular subtypes, but there have 
been no reports investigating whether or not molecular subtyping is predictive of response to 
bevacizumab in ovarian cancer.  
Experimental Design: DASL gene expression arrays were performed on FFPE tissue from patients 
enrolled on the ICON7 trial. Patients were stratified into four TCGA molecular subtypes. 
Associations between molecular subtype and the efficacy of randomly assigned therapy with 
bevacizumab were assessed.  
Results: Molecular subtypes were assigned as follows: 122 immunoreactive (34%), 96 proliferative 
(27%), 73 differentiated (20%), and 68 mesenchymal (19%). In univariate analysis patients with 
tumors of proliferative subtype obtained the greatest benefit from bevacizumab with a median PFS 
improvement of 10.1 months (HR 0.55 [95%CI 0.34-0.90], p=0.016). For the mesenchymal subtype, 
bevacizumab conferred a non-significant improvement in PFS 8.2 months (HR 0.78 [95%CI 0.44-
1.40], p=0.41). Bevacizumab conferred modest improvements in PFS for patients with 
immunoreactive subtype (3.8 months; p=0.08) or differentiated subtype (3.7 months; p=0.61). 
Multivariate analysis demonstrated significant PFS improvement in proliferative subtype patients 
only (HR 0.45 [95%CI 0.27-0.74 p=0.0015]). 
Conclusions: Molecular subtypes with the poorest survival (proliferative and mesenchymal) derive 
a comparably greater benefit from treatment that includes bevacizumab. Validation of our findings in 
an independent cohort could enable the use of bevacizumab for those patients most likely to benefit, 
thereby reducing side effects and healthcare cost. 
 
 
INTRODUCTION 
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Ovarian cancer has the highest mortality rate of all gynecologic malignancies1. Recent progress in 
understanding the molecular biology of epithelial ovarian cancer has not yet translated into 
individualized treatment for these women or improvements in their disease outcome. Most patients 
initially respond to platinum-based chemotherapy but the majority relapse and die from drug-
resistant disease2.This underscores the significant clinical need for more effective and refined 
treatment strategies. Despite classifying epithelial ovarian cancer into high grade serous, 
endometrioid, clear cell and mucinous histologies, the disease continues to be treated with a “one 
size fits all” approach. Gene expression analysis of fresh frozen ovarian cancers performed in the 
Australian Ovarian Cancer Study and The Cancer Genome Atlas (TCGA) has led to a molecular 
classification of four subtypes of high-grade serous (HGS) ovarian cancer: proliferative, 
mesenchymal, immunoreactive and differentiated3,4. In contrast to the original TCGA report, we 
recently demonstrated that these four subgroups have prognostic significance when well-annotated 
with complete clinical follow-up5,6. Furthermore, we demonstrated that these molecular subtypes 
could also be used to classify high grade, advanced stage endometrioid and clear cell ovarian 
cancers6. However, the clinical practice of stratifying ovarian cancer patients into different targeted 
treatment subgroups based on their molecular classification has not yet been adopted.  
In ongoing efforts to refine treatment approaches to ovarian cancer while acknowledging the unique 
biological differences between these four molecular subtypes of the disease, novel targeted agents 
are being developed and investigated.  Of particular interest is, bevacizumab, an anti-angiogenic 
monoclonal antibody that binds to all isoforms of the vascular endothelial growth factor (VEGF)-
receptor ligand VEGF-A.   The Gynecologic Cancer Inter Group (GCIG) International Collaboration 
on Ovarian Neoplasms (ICON7) trial and the Gynecologic Oncology Group study 218 (GOG-218) 
were two phase III trials in ovarian cancer which showed statistically significant improvements in 
median progression free survival (PFS) of 2.3 and 3.8 months, respectively, when bevacizumab was 
added to standard first-line chemotherapy7,8. However, neither trial showed a statistically significant 
improvement in overall survival (OS) in unselected patients. This modest clinical improvement has 
led to limited use of bevacizumab in the frontline treatment of ovarian cancer.  Unfortunately, there 
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are currently no predictive biomarkers that can help to identify patients who would derive a larger 
clinical benefit from frontline treatment with bevacizumab. We now have information, based on 
gene expression data, that the mesenchymal and proliferative ovarian cancer molecular subtypes are 
both defined by overexpression of genes that are relevant to angiogenesis and VEGF-A, the target of 
bevacizumab3-5. Thus, an improved response to bevacizumab in ovarian cancer may be expected if it 
is used as a targeted therapeutic for patients within the angiogenic driven mesenchymal and 
proliferative subgroups. In this current study, we hypothesize that these gene expression-derived 
molecular subtypes can serve as biomarkers to identify patients with differential sensitivity to 
bevacizumab in ovarian cancer. In order to identify TCGA molecular subtypes, whole genome gene 
expression analysis was performed using stored formalin-fixed paraffin-embedded (FFPE) tumors 
from ICON7 trial participants who were treated with and without bevacuzimab4,7.  Clinical data for 
these patients was subsequently analyzed for potential sub-type specific differences in outcome 
when treated with and without bevacizumab. The primary objective of this study was to evaluate the 
therapeutic treatment impact of bevacizumab on PFS based on molecular subtyping.   The secondary 
objective of this study was to assess the impact of treatment with bevacizumab on OS based on 
molecular subtyping,  
 
MATERIAL AND METHODS 
Study Subjects 
Patients were derived from the AGO-OVAR11 trial, the German contribution to the ICON7 
multicenter phase III trial in which patients with peritoneal, tubal or ovarian carcinoma were 
randomized to carboplatin and paclitaxel with or without bevacizumab7. Of 533 patients enrolled in 
the AGO-OVAR11 trial, paraffin-embedded tissue was available for a total of 423 patients with 
primary ovarian, fallopian tube or primary peritoneal cancer confirmed by expert gynecopathologic 
review9,10. Adequate RNA (described below) was available from 391 patients, and expression array 
data for 359 patients passed quality control steps (described below).  This resulted in a total of 359 
patients for further analysis. 
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RNA Isolation 
Using FFPE tumor, three 1mm cores were obtained from areas containing >70% tumor nuclei. Total 
RNA was isolated from these cores using a Qiagen AllPrep DNA/RNA FFPE kit according to the 
manufacturer's protocol using a Qiacube robot. RNA concentration was measured with a ND-1000 
spectrophotometer (NanoDrop, Wilmington, DE, USA). Real time RT-PCR was performed to 
amplify small regions of two abundant mRNAs: the 18S rRNA and gACTB to assess RNA quality.  
 
Whole Genome DASL Microarray Analysis 
Specimens were randomly allocated to RNA extraction and assay run order. In brief, 200 ng of RNA 
was analyzed using the Illumina Whole-Genome DASL HT assay with the HumanRef-8 Bead Chip 
(Cat. No. DA-905-1096) corresponding to 29K gene transcripts or 21K unique genes according to 
the manufacturer's protocol.  
 
Gene Expression Quality Control  
Gene expression data quality was assessed via residual minus versus average plots, box plots, and 
jitter plots to view experimental artifacts such as batch effects10. In addition, numerical measures 
such as stress and dfbeta, measures of the magnitude of change due to normalization, were utilized11. 
Criteria for exclusion were median stress >1 (0 samples were excluded) and median dfbeta >1 (35 
samples were excluded). Data were normalized on the log2 scale via quantile normalization. Per-
probe batch effects remaining after normalization were removed by calculating residuals from per-
probe linear models12.  
 
 
 
Molecular Subtype Assignment 
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Molecular classification was determined blinded to demographic and clinical information. Briefly, 
each given sample was assigned to a subtype according to similarity between observed expression 
and per-subtype expression centroids learned from TCGA. De novo clustering was also performed, 
confirming the existence of four subtypes (Appendix 1). In both TCGA and our own de novo 
clustering studies, consensus clustering approach was used to ensure that only stable clustering 
solutions were kept after multiple re-runs. 
 
Statistical Analysis 
As defined in the original ICON7 report7, primary endpoints were PFS and OS. Kaplan Meier curves 
and log rank tests were used to visualize unadjusted results. As observed previously7, non-
proportional hazards were evident for PFS (p<0.0001). Thus, restricted means hypothesis tests were 
conducted for PFS over the duration of bevacizumab treatment (18 months) and at 36 and 42 months 
for unadjusted models. Restricted means measure the area under the survival curve, and so more 
accurately measure differences in outcome in the presence of non-proportional hazards.  
Covariate-adjusted testing was conducted in a two-step manner. First, similar to a propensity 
score13,14, a clinical risk score was calculated by fitting a Cox regression model to all patients based 
on high risk of progression (ICON 7 high risk group: suboptimally cytoreduced Stage III  with >1.0 
cm residual disease at the end of surgery, inoperable Stage III, all Stage IV )7, age (continuous), 
histology (serous; other), and grade (1, 2 or  3). Second, the predicted value, the ܺߚመ , was used as an 
offset in Cox models. Given the sample size, we focused on effect size and report actual p-values, 
using 0.05 as an indicator of statistical significance, and utilized Bonferroni multiple testing criteria 
for subgroup comparisons. 
 
 
 
 
RESULTS 
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Patient Cohort 
The baseline characteristics of the 359 patients included in the analysis were well balanced between 
treatment groups (Table 1). 77.2% of tumors were of serous histology and one third of patients were 
at high risk of progression. An optimal cytoreduction (to residual disease of < 1 cm) was performed 
in 76.3% of patients. At a median follow-up of 26.9 months (range 0 – 43.6), 226 patients (63%) had 
a PFS event and 91 patients (25%) had died.  
 
TCGA-defined Molecular Subtype Determination 
Molecular subtype assignment was as follows: 73 differentiated (20%), 122 immunoreactive (34%), 
68 mesenchymal (19%), and 96 proliferative (27%). These frequencies are comparable to those 
found in prior studies4. When we applied unsupervised non-negative matrix factorization (NMF) 
clustering with k=4 groups, the average cophenetic coefficient was 0.993, indicating high 
reproducibility of this classification (Chi square test P<0.001) (Figure S1, 2). Baseline characteristics 
within molecular subgroups are shown in Table 2. Among mesenchymal and proliferative 
subgroups, 43% and 42% patients, respectively, met the criteria of the ICON7 high risk group, 
compared to 25% and 26% in the differentiated and immunoreactive subgroups, respectively4. 
Consistent with prior reports, patients with mesenchymal and proliferative tumors also had inferior 
PFS compared to the differentiated and immunoreactive subgroups (Figure 1)5,6.  
 
Bevacizumab Effects on PFS by Molecular Subtype 
Univariate analysis was performed for PFS between treatment arms stratified by molecular subtypes 
using standard Kaplan-Meier.  Multivariate analysis was then performed using Cox model analyses, 
adjusting for high risk of progression (suboptimal stage III, inoperable Stage III, and all stage IV 
patients), age, grade, and histology. Patients with proliferative and mesenchymal tumors obtained 
greater benefit from bevacizumab than did the immunoreactive or differentiated subgroups. Among 
the proliferative subgroup, median PFS improved by 10.1 months and was statistically significant 
(21.9 versus 11.8 months, unadjusted HR 0.55 [95% CI 0.34-0.90], p=0.016; adjusted HR 0.45 [95% 
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CI 0.27-0.74], p=0.0015)) (Figure 1A, Table 3). In the mesenchymal subtype, non-significant 
prolongations in PFS of 8.2 months (20.6 versus 12.4 months, unadjusted HR 0.78 [95% CI 0.44-
1.40], p=0.41). The immunoreactive subtype demonstrated a non-significant prolongation in PFS of 
3.8 months (20.8 versus 17 months; unadjusted HR 0.67 [95% CI 0.42-1.05], p=0.08) (Figure 1C, 
Table 3). The prolongation in PFS in the differentiated subtype was 3.7 months (21.6 versus 17.9 
months, unadjusted HR 0.85 [95% CI 0.46-1.85], p=0.61) (Figure 1D, Table 3). Changes in PFS for 
the mesenchymal, immunoreactive, and differentiated groups remained non-significant in 
multivariate analysis (Table 3).  
 
Bevacizumab Effects on OS by Molecular Subtype 
The overall survival data was not mature at the time of analysis, but preliminary analysis was 
performed using OS between treatment arms in molecular subtypes in a univariate analysis by 
standard Kaplan-Meier and in a multivariate analysis using Cox model analyses, adjusting for high 
risk of progression (suboptimal stage III, inoperable Stage III, and all stage IV patients), age, grade, 
and histology. The proliferative subtype showed a trend towards improved OS (median not reached, 
unadjusted HR 0.52 [95% CI 0.25-1.08], p=0.08; adjusted HR 0.50 [95% CI 0.24-1.03], p=0.06) 
(Figure 2A, Table 3). In the mesenchymal subtype OS (unadjusted HR of 0.56] 95% CI 0.23-1.34], 
p=0.19) were observed (Figure 2B, Table 3). The immunoreactive subtype demonstrated an OS 
unadjusted HR of 0.76 [95% CI 0.33-1.76], p=0.52) (Figure 2C, Table 3). The differentiated subtype 
OS was unadjusted HR of 1.41 [95% CI 0.53-3.71], p=0.49) (Figure 2D, Table 3). 
Changes in OS for the mesenchymal, immunoreactive, and differentiated groups remained non- 
significant in multivariate analysis (Table 3). 
 
Restricted Means Analysis for PFS by Molecular Subtype 
As reported in the primary results for the clinical trial, there was a significant violation of the 
assumption of proportional hazards. Thus, we also assessed the effect of bevacizumab on PFS using 
a restricted means approach, as performed in the parent trial. During the first 18 months of therapy, 
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which corresponds to the treatment duration of bevacizumab, the strongest bevacizumab treatment 
effect was observed in the proliferative group (p=0.0004) followed by the mesenchymal subgroup 
(p=0.0121); this treatment effect persisted within the proliferative subgroup only, as seen at   36 
months (p=0.010) and 42 months (p=0.011) respectively (Table S1). 
 
 
Bevacizumab Treatment Effects on PFS and OS 
For all patients, there was an improvement in median PFS for the bevacizumab arm compared to the 
standard arm of 6.5 months (21.1 vs. 14.6, unadjusted HR 0.68 [95% CI 0.53-0.89], p=0.005) 
(Figure S3A, Table 3). When adjusted for high risk of progression, age, grade, and histology, Cox 
regression analysis demonstrated that bevacizumab conferred significant improvements in PFS 
(adjusted HR 0.64 [95% CI 0.49-0.83], p=0.0008), but OS was of borderline significance 
(unadjusted HR 0.68, [95% CI 0.45-1.03], p=0.07; adjusted HR 0.66, [95% CI 0.44-1.00], p=0.05) 
(Table 3).  
 
CONCLUSION 
The precise role of anti-angiogenic therapy of ovarian cancer continues to evolve.  While both   
GOG 218 and ICON7 showed improvement in progression free survival with the addition of 
bevacizumab to standard platinum based chemotherapy in the treatment of ovarian cancer, predicting 
which patients will derive the greatest benefit from this anti-angiogenic therapy  has remained 
challenging.  Through work performed by the Australian Ovarian Cancer Study, the TCGA and our 
own group, gene expression analysis has identified four distinct molecular subtypes of high grade 
serous ovarian cancer with prognostic significance.  Of these four types, the mesenchymal and 
proliferative subtype share an angiogenic gene expression signature and may respond to anti-
angiogenic therapy. 
Therefore, through this work, we investigated whether molecular subtyping by gene expression 
analysis could identify ovarian cancer patients who would preferentially benefit, in terms of PFS and 
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OS, from the addition of bevacizumab to standard initial systemic therapy.  Using archival tumor 
samples from a subset of women with ovarian cancer treated on the randomized ICON7 trial, we 
were able to reclassify these patients into four different molecular subtypes and analyze clinical 
response with and without the addition of bevacizumab. Overall, we were able to demonstrate that 
the addition of bevacizumab to carboplatin and paclitaxel in all patients resulted in a significant 
improvement in PFS of 6.5 months, but OS was not prolonged, reflecting the original findings from 
the ICON7 trial7. When assessing clinical response between all four TCGA molecular subtypes, the 
patients with proliferative tumors who received bevacizumab had a prolongation in PFS of 10.1 
months compared to the standard control arm (no bevacizumab). This improvement in PFS for the 
proliferative group remained statistically significant even after adjusting for age, grade, histology, 
and high risk of progression (HR 0.45, p=0.0015). In addition, bevacizumab exerted a strong effect 
in the mesenchymal subtype with the largest benefit over the period of therapy (18 months, restricted 
means analysis). The immunoreactive subtype was the largest subtype (34%), yet showed a modest 
PFS effect (median increase in PFS of 3.8 months, p=0.08) when treated with bevacizumab but this 
was not accompanied by a survival benefit. Finally, patients with the differentiated molecular 
subtype showed the weakest treatment effect (increase in median PFS of 3.7 months, p=0.61) from 
bevacizumab and no survival benefit (OS HR=1.41, 95% CI: 0.53-3.71, p=0.49). 
Based on findings in four large phase III trials (GOG 218, ICON7, OCEANS, AURELIA), 
bevacizumab was approved for first-line treatment of patients with newly diagnosed, advanced 
ovarian carcinoma by the European Medicines Agency. However, considering its lack of impact on 
OS, bevacizumab has not been granted approval by the United States Food and Drug Administration 
for the treatment of primary ovarian cancer. Realizing these limitations in recommending treatment 
for all patients with primary ovarian cancer with bevacizumab, our results may provide support for 
treatment of a subset of patients with ovarian cancer, thereby improving benefit while reducing risk 
for adverse events and treatment cost. To our knowledge, this report is the first to investigate 
possible molecular predictors of response to bevacizumab utilizing a randomized, placebo-controlled 
trial of patients with primary ovarian cancer. Others have used retrospective approaches to study 
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genetic alterations associated with anti-angiogenic response, or mechanisms that may contribute to 
resistance. For example, in an analysis of 84 ovarian cancer samples, expression of Notch/Delta-like 
ligand 4 was shown to be lower in tumors from patients who responded to bevacizumab15.  
Usingtranscriptional profiling on 129 ovarian cancers, an “angiogenesis signature” was described 
and validated in ten gene expression datasets and associated with improved OS16, but an unknown 
number of patients were treated with bevacizumab. For the current study, we hypothesized that 
bevacizumab may be more effective in those subtypes (the mesenchymal and proliferative) with 
upregulation of proangiogenic genes and/or upregulation of stromal components that may secrete 
proangiogenic factors. For example, overexpression of SOX11, a defining alteration in the 
proliferative subtype, is associated with increased microvessel density17. Mesenchymal tumors are 
characterized by HOX upregulation, an important promoter of capillary morphogenesis and 
angiogenesis through VEGF18,19. Interestingly, the mesenchymal subtype of glioblastoma, a tumor 
which can also be divided into four unique molecular subtypes based on gene expression profling20, 
has the worst overall prognosis but appears to have an improved response to bevacuzimab21 and is 
currently the subject of ongoing clinical investigation [http://clinicaltrials.gov/show/NCT01392209]. 
In addition, a recent study from Sandmann et al. used a NanoString based gene expression molecular 
classifier to stratify patients treated in the phase III frontline glioblastoma AVAglio trial into 
established molecular subtypes. All patients in this study who were treated with bevacizumab had an 
improvement of PFS but without an OS benefit. However, when stratified by molecular subtype, the 
proneural group showed a significant improvement in PFS and OS with the addition of 
bevacuzimab22.  As in our current study, the work by Sandmann et al. demonstrated the feasibility of 
clinical application of gene expression based classifiers to select patients benefiting most from 
antiangiogenic treatment22. Additional studies in breast cancer and lymphoma have implemented 
clinically reliable and reproducible subtyping assays in other cancers23,24. 
 
Our study sought to establish the validity of stratifying ovarian cancer patients into molecular 
subtypes based on gene expression data to predict response to bevacizumab.  Our results are 
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strengthened by the use of samples from a large, randomized controlled clinical trial comparing the 
addition of bevacizumab to standard treatment versus standard treatment alone, with high quality 
robust clinical follow-up.  Importantly, we were able to demonstrate the ability to obtain high quality 
gene expression data from FFPE tissues in 85% of cases. The Australian Ovarian Cancer Study 
Group has recently evaluated the feasibility of using FFPE tissue in comparison to fresh frozen 
tissue from the same tumor and were able to correctly classify 80% of the FFPE samples25. In 
addition, they compared 1) PCR-based assays (low density arrays and Fluidigm), 2) the fluorescent 
oligonucleotide array NanoString and 3) a targeted RNA sequencing assay (Illumina). The 
NanoString assay emerged as the best clinically applicable platform and can be used in individual 
patients for molecular subtype assignment25,26. The utility of molecular subtype assignment using the 
NanoString platform is currently being validated in 3000 retrospective ovarian cancer samples, by 
the Ovarian Tumor Tissue Analysis (OTTA) consortium. The use of FFPE has important clinical 
practicality in contrast to the TCGA’s use of fresh frozen material which is less readily available and 
inconvenient to transport. Finally, an additional strength of our data lies in the fact that rather than 
creating another de novo molecular classification, we used the four gene signatures previously 
described by the Australian Ovarian Cancer Study3 and validated by TCGA4. In contrast to the 
original TCGA report, we recently demonstrated that these four subgroups have prognostic 
significance when well-annotated with complete clinical follow-up5,6. The proliferative and 
mesenchymal signatures had shorter survival when compared to the immunoreactive group (adjusted 
OR 1.52, 1.84, respectively). It is encouraging that bevacizumab appears to confer the greatest 
benefit for the two molecular subgroups (proliferative and mesenchymal) with the worst prognosis. 
Interestingly, these two subtypes also showed the greatest benefit over the duration of bevacizumab 
therapy, which rapidly diminished following cessation of treatment. This suggests merit in 
investigating prolongation of bevacizumab therapy in patients with proliferative or mesenchymal 
tumors. 
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In this current work, we analyzed only a subset of the entire population of women treated on ICON7 
but could be further strengthened by analysis of a replication cohort which was not available.   
One limitation of our study was that it was limited to the German AGO samples. The number of 
missing data, due to missing available FFPE tissue, limited tumor tissue or purity, could skewthe 
remaining data to larger tumors that had inherently more available FFPE tissue. Different 
institutional protocols in preparation of the FFPE tumor tissue used in this study could also have had 
influence on the RNA quality and subsequent successful DASL array data in this study. However the 
samples were obtained from 98 different participating study sites in Germany, reducing the risk of 
site specific sample preparation. Importantly, our set mirrors the stages and histologies of all women 
enrolled, and like the parent trial7, a statistically significant improvement in PFS, but not OS, was 
observed as a result of treatment with bevacizumab. This feature of the trial, as well as the 
proportional hazards violation of the PFS Cox model, led us to examine outcomes using multiple 
methods. We have provided all results and our conclusions reflect inference across the analytical 
techniques. Reported p values have not been penalized for multiple comparisons, but we have 
indicated when a p-value has met the Bonferroni multiple comparison cutoff in the tables; actual p-
values have been reported so that the reader can impose multiple comparison penalties if they wish  
Interaction p-values are not reported due to severe lack of power.  Finally, because of our limited 
cohort size, we could not demonstrate a statistically significant impact on OS in the proliferative 
subgroup. Similarly, this study was not powered to show statistically significant differences in PFS 
improvement between molecular subgroups. We nevertheless consider differences in the magnitude 
of PFS improvement within each subtype to be clinically relevant.  
In order to move towards clinical application of gene expression based subtyping in ovarian cancer, 
our findings need to be validated retrospectively in a validation cohort. Despite significant 
differences between the ICON7 and the GOG218 trial ( placebo controlled, did not include low stage 
patients and used a higher dose of bevacizumab), it might be the best possible validation cohort to 
date7,8. Furthermore, newer gene expression assays, like the NanoString platform, which can be used 
in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory to molecular 
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subtype ovarian cancer patients, open the possibility of prospective clinical trials to enrich for 
specific molecular subtypes25,26. Furthermore, our group is currently initiating an investigator 
initiated Phase II, open-label, single-arm, multi-center study to evaluate efficacy and safety of 
pembrolizumab monotherapy in subjects with advanced epithelial ovarian cancer whose tumor 
specimens demonstrate an immunoreactive gene expression signature. We will utilize the 
NanoString platform in a CLIA certified laboratory to screen and classify patients into one of the 
four molecular subtypes using FFPE tumor tissue. The same approach could be used to conduct 
prospective trials enriching for patients with molecular subtypes deriving more possible benefit from 
treatment with bevacizumab.  
In summary, the present investigation is the first to examine the correlation of molecular subtype 
with outcome after treatment with bevacizumab in a randomized controlled phase III trial of primary 
ovarian cancer. We showed that women with the proliferative and mesenchymal molecular subtypes 
appear to benefit most, with a prolongation in PFS and a trend toward greater OS. Validation of our 
findings in an independent cohort, like GOG 218 could enable the targeted use of bevacizumab for 
selected patients, based on their molecular subtype. 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Baseline characteristics by treatment arm 
17 
 
 
 
Bevacizumab
(N=189) 
Standard 
(N=170) 
Total 
(N=359) 
Molecular subgroup       
    Differentiated 36 (19.0%) 37 (21.8%) 73 (20.3%) 
    Immunoreactive 69 (36.5%) 53 (31.2%) 122 (34.0%) 
    Mesenchymal 37 (19.6%) 31 (18.2%) 68 (18.9%) 
    Proliferative 47 (24.9%) 49 (28.8%) 96 (26.7%) 
Age (years) at randomization       
    Mean (SD) 58.1 (11.0) 57.4 (11.2) 57.8 (11.1) 
    Range (26.0-80.0) (21.0-80.0) (21.0-80.0) 
Race       
    White 189 (100.0%) 167 (98.2%) 356 (99.2%) 
    Asian 0 (0.0%) 3 (1.8%) 3 (0.8%) 
ECOG score       
    0 77 (40.7%) 78 (45.9%) 155 (43.2%) 
    1 93 (49.2%) 83 (48.8%) 176 (49.0%) 
    2 19 (10.1%) 9 (5.3%) 28 (7.8%) 
Origin of cancer       
    Ovary  169 (89.4%) 150 (88.2%) 319 (88.9%) 
    Fallopian tube 7 (3.7%) 7 (4.1%) 14 (3.9%) 
    Primary peritoneum 12 (6.3%) 12 (7.1%) 24 (6.7%) 
    Multiple sites 1 (0.5%) 1 (0.6%) 2 (0.6%) 
Histology       
    Serous 150 (79.4%) 127 (74.7%) 277 (77.2%) 
    Clear cell 7 (3.7%) 7 (4.1%) 14 (3.9%) 
    Endometrioid 4 (2.1%) 6 (3.5%) 10 (2.8%) 
    Mucinous 3 (1.6%) 2 (1.2%) 5 (1.4%) 
    Mixed 15 (7.9%) 21 (12.4%) 36 (10.0%) 
    Other 10 (5.3%) 7 (4.1%) 17 (4.7%) 
FIGO stage       
    I/IIA 14 (7.4%) 12 (7.1%) 26 (7.2%) 
    IIB/IIC 12 (6.3%) 11 (6.5%) 23 (6.4%) 
    III 134 (70.9%) 117 (68.8%) 251 (69.9%) 
    IV 29 (15.3%) 30 (17.6%) 59 (16.4%) 
Outcome of surgery       
    Optimal 145 (76.7%) 129 (75.9%) 274 (76.3%) 
    Sub-Optimal 43 (22.8%) 40 (23.5%) 83 (23.1%) 
    missing 1 (0.5%) 1 (0.6%) 2 (0.6%) 
High-risk of progression*       
    No 130 (68.8%) 110 (64.7%) 240 (66.9%) 
    Yes 59 (31.2%) 60 (35.3%) 119 (33.1%) 
Grade       
    1 or 2 46 (24.5%) 28 (16.8%) 74 (20.8%) 
    3 142 (75.5%) 139 (83.2%) 281 (79.2%) 
    Missing 1 3 4 
                *High risk of progression: suboptimal debulked stage III, inoperable Stage III, all stage IV patients.  
Table 2: Baseline Characteristics by Molecular Subgroups 
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Differentiated 
(N=73) 
Immunoreactive 
(N=122) 
Mesenchymal 
(N=68) 
Proliferative 
(N=96) 
Total 
(N=359) 
Treatment           
    Bevacizumab 36 (49.3%) 69 (56.6%) 37 (54.4%) 47 (49.0%) 189 (52.6%) 
    Standard 37 (50.7%) 53 (43.4%) 31 (45.6%) 49 (51.0%) 170 (47.4%) 
Age (years) at randomization           
    Mean (SD) 52.0 (12.9) 57.0 (9.8) 59.5 (11.3) 62.0 (9.1) 57.8 (11.1) 
    Range (21.0-75.0) (35.0-77.0) (21.0-80.0) (37.0-80.0) (21.0-80.0) 
Race           
    White 73 (100.0%) 122 (100.0%) 65 (95.6%) 96 (100.0%) 356 (99.2%) 
    Asian 0 (0.0%) 0 (0.0%) 3 (4.4%) 0 (0.0%) 3 (0.8%) 
ECOG score           
    0 29 (39.7%) 64 (52.5%) 23 (33.8%) 39 (40.6%) 155 (43.2%) 
    1 38 (52.1%) 45 (36.9%) 42 (61.8%) 51 (53.1%) 176 (49.0%) 
    2 6 (8.2%) 13 (10.7%) 3 (4.4%) 6 (6.3%) 28 (7.8%) 
Origin of cancer           
    Ovary  73 (100.0%) 105 (86.1%) 57 (83.8%) 84 (87.5%) 319 (88.9%) 
    Primary peritoneal 0 (0.0%) 8 (6.6%) 8 (11.8%) 8 (8.3%) 24 (6.7%) 
    Fallopian tube 0 (0.0%) 7 (5.7%) 3 (4.4%) 4 (4.2%) 14 (3.9%) 
    Multiple sites 0 (0.0%) 2 (1.6%) 0 (0.0%) 0 (0.0%) 2 (0.6%) 
Histology           
    Serous 53 (72.6%) 91 (74.6%) 56 (82.4%) 77 (80.2%) 277 (77.2%) 
    Clear cell 5 (6.8%) 5 (4.1%) 3 (4.4%) 1 (1.0%) 14 (3.9%) 
    Endometrioid 3 (4.1%) 2 (1.6%) 1 (1.5%) 4 (4.2%) 10 (2.8%) 
    Mucinous 1 (1.4%) 1 (0.8%) 3 (4.4%) 0 (0.0%) 5 (1.4%) 
    Mixed 9 (12.3%) 13 (10.7%) 3 (4.4%) 11 (11.5%) 36 (10.0%) 
    Other 2 (2.7%) 10 (8.2%) 2 (2.9%) 3 (3.1%) 17 (4.7%) 
FIGO stage           
    I/IIA 8 (11.0%) 8 (6.6%) 3 (4.4%) 7 (7.3%) 26 (7.2%) 
    IIB/IIC 10 (13.7%) 8 (6.6%) 1 (1.5%) 4 (4.2%) 23 (6.4%) 
    III 44 (60.2%) 91 (73.7%) 50 (73.6%) 66 (68.7%) 251 (69.8%) 
    IV 11 (15.1%) 15 (12.3%) 14 (20.6%) 19 (19.8%) 59 (16.4%) 
Grade           
    1 or 2 28 (38.9%) 16 (13.3%) 15 (22%) 15 (15.8%) 74 (20.8%) 
    3 44 (61.1%) 104 (86.7%) 53 (77.9%) 80 (84.2%) 281 (79.2%) 
    Missing 1 2 0 1 4 
Outcome of surgery           
    Optimal (< 1cm residual tumor) 59 (80.8%) 99 (81.1%) 48 (70.6%) 68 (70.8%) 274 (76.3%) 
    Sub-Optimal (>1cm residual tumor) 13 (17.8%) 22 (18.0%) 20 (29.4%) 28 (29.2%) 83 (23.1%) 
    Inoperable 1 (1.4%) 1 (0.8%) 0 (0.0%) 0 (0.0%) 2 (0.6%) 
High-risk of progression*           
    No 55 (75.3%) 90 (73.8%) 39 (57.4%) 56 (58.3%) 240 (66.9%) 
    Yes 18 (24.7%) 32 (26.2%) 29 (42.6%) 40 (41.7%) 119 (33.1%) 
*High risk of progression suboptimal debulked stage III, inoperable Stage III, all stage IV. 
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Table 3:  Unadjusted and adjusted progression free and overall survival in patients treated with 
bevacizumab vs. standard treatment, stratified by TCGA molecular subtype 
 
 Progression Free Survival Overall Survival  
 Unadjusted Adjusted Unadjusted Adjusted 
 
HR  
(95% CI) 
p-
value 
HR  
(95% CI) p-value 
HR  
(95% CI) 
p-
value 
HR (95% 
CI) p-value 
All (n=359) 
0.68  
(0.53-0.89) 0.005 
0.64  
(0.49-0.83) 
0.0.000
8 
0.68  
(0.45-1.03) 0.07 
0.66  
(0.44-1.00) 0.05 
Mesenchymal 
(n=68) 
0.78  
(0.44-1.40) 0.41 
0.80  
(0.45-1.43) 0.45 
0.56  
(0.23-1.34) 0.19 
0.55  
(0.23-1.32) 0.18 
Proliferative 
(n=96) 
0.55  
(0.34-0.90) 0.016 
0.45  
(0.27-0.74) 0.0015* 
0.52  
(0.25-1.08) 0.08 
0.50  
(0.24-1.03) 0.06 
Immunoreactive 
(n=122) 
0.67  
(0.42-1.05) 0.08 
0.66  
(0.42-1.05) 0.08 
0.76  
(0.33-1.76) 0.52 
0.72  
(0.31-1.67) 0.45 
Differentiated 
(n=73) 
0.85  
(0.46-1.58) 0.61 
0.75  
(0.40-1.39) 0.36 
1.41  
(0.53-3.71) 0.49 
1.55  
(0.59-4.10) 0.38 
 *P value for subgroup comparison significant after Bonferroni correction. Adjusted analyses included high risk of progression (suboptimal stage 
III, inoperable Stage III,and all stage IV patients), age, grade, and histology. 
 
 
 
 
Figure 1: Kaplan Meier analysis of progression free survival for bevacizumab vs. standard treatment 
stratified by TCGA subtype. 
 
Figure 2: Kaplan Meier analysis of overall survival for bevacizumab vs. standard treatment in patients, 
stratified by TCGA subtype. 
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